Groupe Hospitalier Paris Saint Joseph   Report issue

Academic/Hospital Phase 2 Phase 3
Founded: Paris France (1878)

Organization Overview

First Clinical Trial
2001
NCT00198354
First Marketed Drug
None
First NDA Approval
None
Last Known Activity
2022

Timeline

NOW
  • Now

Alternative names

CH Paris Saint Joseph - Paris | Groupe Hospitalier Paris Saint Joseph | Groupe Hospitalier Paris Saint-Joseph (FRANCE) | Groupe Hospitalier Saint Joseph | IFCT | IFCT, GH Paris Saint-Joseph | IFCT, HCL Lyon-Sud

Indications

Experimental Indications (Clinical Trials, Phases 1-4)


 

Adenocarcinoma (Phase 3)

Adenocarcinoma of Lung (Phase 2)

Carcinoma, Non-Small-Cell Lung (Phase 3)

Communicable Diseases (Phase 3)

Diabetes Mellitus, Type 2 (Phase 2)

Esophageal Neoplasms (Phase 2)

Infections (Phase 3)

Lung Neoplasms (Phase 2)

Mesothelioma (Phase 3)

Neoplasms (Phase 2)

Prostatic Neoplasms (Phase 3)

Recurrence (Phase 3)

Small Cell Lung Carcinoma (Phase 2)

Stomach Neoplasms (Phase 2)

Urinary Tract Infections (Phase 3)

Weight Loss (Phase 2)

Overview

  • Highest Phase: Phase 3
  • # of Trials: 18
  • # of Trial APIs: 36